



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

S1RA

Cat. No.:	HY-18099
CAS No.:	878141-96-9
Molecular Formula:	C ₂₀ H ₂₃ N ₃ O ₂
Molecular Weight:	337.42
Target:	Sigma Receptor; 5-HT Receptor
Pathway:	Neuronal Signaling; GPCR/G Protein
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

1M HCl : 50 mg/mL (148.18 mM; ultrasonic and adjust pH to 1 with HCl)
 DMSO : 33.33 mg/mL (98.78 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.9637 mL	14.8183 mL	29.6367 mL
	5 mM		0.5927 mL	2.9637 mL	5.9273 mL
	10 mM		0.2964 mL	1.4818 mL	2.9637 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 2.5 mg/mL (7.41 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

S1RA (E-52862) is a highly selective σ₁ receptor (σ₁R) antagonist with K_is of 17 nM and 23.5 nM for human σ₁R and guinea pig σ₁R, respectively. S1RA has Moderate antagonistic activity for human 5-HT_{2B} receptor (K_i= 328 nM). S1RA has antinociceptive effects in neuropathic pain models. S1RA prevents mechanical and cold hypersensitivity in Oxaliplatin (HY-17371)-treated mice^{[1][2]}.

IC₅₀ & Target

human σ ₁ R	guinea pig σ ₁ R	guinea pig σ ₂ R	rat σ ₂ R
------------------------	-----------------------------	-----------------------------	----------------------

	17 nM (Ki)	23.5 nM (Ki)	>1000 nM (Ki)	9300 nM (Ki)								
	human 5-HT _{2B} Receptor 328 nM (Ki)											
In Vitro	S1RA (E-52862; 100 μM; 4 h) inhibit intracellular calcium responses in TRPA1 expressing HEK293 cells^[2]. S1RA (100 μM; 4 h) impairs the formation of TRPA1–Sigma-1R complexes and reduces TRPA1 expression at the plasma membrane^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.											
In Vivo	S1RA (E-52862; 40 mg/kg; IP; single dose) produces a substantial reduction in pain-related responses to intradermal Allylisothiocyanate (AITC) in WT mice^[2]. S1RA (40 mg/kg; IP; once a day for 11 consecutive days; starting 3 days before Oxaliplatin injection) prevents mechanical and cold hypersensitivity in Oxaliplatin (6 mg/kg; i.p.; Day 0, Day 2, Day 4)-treated mice^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. <table><tr><td>Animal Model:</td><td>WT and TRPA1 KO mice with AITC (10 μl at 10 mM) in their hind paws^[2]</td></tr><tr><td>Dosage:</td><td>40 mg/kg</td></tr><tr><td>Administration:</td><td>IP; single dose; 24-h before evaluation</td></tr><tr><td>Result:</td><td>Produced a substantial reduction in pain-related responses to intradermal AITC in WT mice.</td></tr></table>				Animal Model:	WT and TRPA1 KO mice with AITC (10 μl at 10 mM) in their hind paws ^[2]	Dosage:	40 mg/kg	Administration:	IP; single dose; 24-h before evaluation	Result:	Produced a substantial reduction in pain-related responses to intradermal AITC in WT mice.
Animal Model:	WT and TRPA1 KO mice with AITC (10 μl at 10 mM) in their hind paws ^[2]											
Dosage:	40 mg/kg											
Administration:	IP; single dose; 24-h before evaluation											
Result:	Produced a substantial reduction in pain-related responses to intradermal AITC in WT mice.											

CUSTOMER VALIDATION

- Eur J Med Chem. 5 August 2022, 114649.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Díaz JL, et al. Synthesis and biological evaluation of the 1-arylpyrazole class of $\sigma(1)$ receptor antagonists: identification of 4-[2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl]morpholine (S1RA, E-52862). J Med Chem. 2012 Oct 11;55(19):8211-24.

[2]. Aida Marcotti, et al. TRPA1 modulation by Sigma-1 receptor prevents oxaliplatin-induced painful peripheral neuropathy. Brain. 2023 Feb 13;146(2):475-491.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA